

**REMARKS**

This Preliminary Amendment is being made upon entry of International Application No. PCT/EP00/02467 into the U.S. National Phase of prosecution. Claims 1-9, 11, 12, 14, and 15 are pending in this application. Claims 3, 4, 5, 7, 8, 11, 12, and 14 have been amended. Claims 10 and 13 have been canceled.

Furthermore, attached hereto is a marked-up version of the changes made to the application by the current preliminary amendment. The attached page is captioned, "**Version with markings to show changes made.**"

Respectfully submitted,



William R. Majarian  
Attorney for Applicants  
Registration No. 41,173

GLAXOSMITHKLINE  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5968  
Facsimile (610) 270-5090  
N:\Will\APPS\B45182\usnatpreamend.doc

09936988-12491  
T06T2T "5869E660

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the specification:**

**--CROSS REFERENCES TO RELATED APPLICATIONS--**

This newly added paragraph to the specification is solely to incorporate continuing application data. No changes have been made. Therefore, a marked up version is not required.

The newly added page to the specification is solely to incorporate the Abstract page. No changes have been made. Therefore, a marked up version is not required.

**In the claims:**

3. (Amended) The immunogenic composition of claim[s] 1[or 2], wherein the protein antigen is a toxin, adhesin or lipoprotein of *Streptococcus pneumoniae* or immunologically functional equivalents thereof.
4. (Amended) The immunogenic composition of claim[s] 1[-3], wherein the protein antigen or immunologically functional equivalent thereof is selected from the group: pneumolysin, PspA or transmembrane deletion variants thereof, PspC or transmembrane deletion variants thereof, PsaA or transmembrane deletion variants thereof, glyceraldehyde-3-phosphate dehydrogenase, and CbpA or transmembrane deletion variants thereof.
5. (Amended) The immunogenic composition of claim[s] 1[-4], wherein the polysaccharide antigen is presented in the form of a polysaccharide-protein carrier conjugate.
7. (Amended) An immunogenic composition [as claimed in any]of claim[s] 1[to 6] which comprises at least four pneumococcal polysaccharide antigens from different serotypes.

8. (Amended) An immunogenic composition as claimed in [any of]claim[s] 1[to 7], wherein the adjuvant comprises at least one of the following: 3D-MPL, a saponin immunostimulant, or an immunostimulatory CpG oligonucleotide.

11. (Amended) A vaccine comprising the immunogenic composition of claim[s] 1[-9].

12. (Amended) A method of preventing or ameliorating *Streptococcus pneumoniae* infection in a patient over 55 years[,] of age, comprising administering an effective amount of a vaccine comprising a *Streptococcus pneumoniae* polysaccharide, at least one *Streptococcus pneumoniae* protein, and a TH1 inducing adjuvant.

14. (Amended) A method of making the immunogenic composition of claim[s] 1[-10], comprising the steps of:  
selecting one or more pneumococcal polysaccharide antigen(s);  
selecting one or more pneumococcal protein antigen(s);  
selecting a TH1 inducing adjuvant; and  
mixing said polysaccharide and protein antigens and adjuvant with a suitable excipient.

09936583.121901